Related Experiment Videos
Omalizumab in asthma: approval and postapproval experience
Dean T Chiang1, Justin Clark, Thomas B Casale
1Division of Allergy and Immunology, Creighton University Medical Center, Omaha, NE, USA.
Clinical Reviews in Allergy & Immunology
|October 14, 2005
Summary
Omalizumab, a monoclonal antibody, effectively treats moderate-to-severe allergic asthma by reducing immunoglobulin E (IgE) levels. It also shows efficacy in allergic rhinitis, demonstrating a favorable safety profile.
Area of Science:
- Immunology
- Pharmacology
- Allergy Research
Background:
- Immunoglobulin E (IgE) plays a central role in allergic inflammation.
- Elevated IgE levels are associated with conditions like asthma and allergic rhinitis.
- Targeting IgE offers a therapeutic strategy for allergic diseases.
Purpose of the Study:
- To review the efficacy and safety of omalizumab in treating allergic asthma and allergic rhinitis.
- To elucidate the mechanism of action of omalizumab.
- To summarize its approved indications and patient populations.
Main Methods:
- Omalizumab is a humanized monoclonal antibody targeting the IgE heavy chain.
- It reduces free serum IgE and FcepsilonRI receptor expression.
- Clinical studies evaluated its impact on airway inflammation and symptoms.
Main Results:
- Omalizumab demonstrated efficacy in moderate-to-severe persistent allergic asthma.
- It is approved for allergic asthma in patients aged 12 and older.
- Effective in treating seasonal and perennial allergic rhinitis in children and adults.
Conclusions:
- Omalizumab is an effective treatment for allergic asthma and allergic rhinitis.
- Its mechanism involves reducing IgE-mediated inflammation.
- Postmarketing surveillance indicates a good safety and tolerability profile.